| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Nolan Sean P. | Chief Executive Officer, Director | C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS | /s/ Kamran Alam, Attorney-in-Fact | 27 Jan 2026 | 0001569926 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TSHA | Common Stock | Sale | $649,748 | -136,789 | -4.4% | $4.75 | 2,949,569 | 23 Jan 2026 | Direct | F1, F2 |
| transaction | TSHA | Common Stock | Sale | $190,448 | -41,312 | -1.4% | $4.61 | 2,908,257 | 26 Jan 2026 | Direct | F1, F3 |
| holding | TSHA | Common Stock | 1,535,545 | 23 Jan 2026 | See footnote | F4 |
| Id | Content |
|---|---|
| F1 | The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. |
| F2 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). |
| F3 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive. |
| F4 | The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC. |